Humacyte, Inc.
HUMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | -0.00 | 0.22 | 0.12 |
| FCF Yield | -16.66% | -25.73% | -33.19% | -28.09% |
| EV / EBITDA | -4.31 | -2.81 | -1.54 | -1.69 |
| Quality | ||||
| ROIC | -94.67% | -89.06% | -43.24% | -29.26% |
| Gross Margin | 0.00% | 0.00% | -427.48% | -4,756.77% |
| Cash Conversion Ratio | 0.66 | 0.66 | 5.94 | 3.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 1.63% | -41.12% |
| Free Cash Flow Growth | -31.90% | -4.72% | 11.34% | -45.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.24 | 1.31 | 2.28 |
| Interest Coverage | -12.33 | -15.16 | -13.64 | -18.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -227.93 | -30.95 | -63.29 | 38.40 |